Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INVITAE CORPORATION

(NVTA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Invitae : to Acquire Consumer Health Tech Company Ciitizen in $325 Million Deal

09/07/2021 | 07:54am EST


ę MT Newswires 2021
All news about INVITAE CORPORATION
11/09INVITAE CORP Management's Discussion and Analysis of Financial Condition and Results o..
AQ
11/09Invitae to Seek Acquisition
CI
11/09Raymond James Adjusts Price Target on Invitae to $36 From $38, Maintains Outperform Rat..
MT
11/09Healthcare Stocks Inching Lower in Premarket Tuesday
MT
11/09Wells Fargo Adjusts Invitae's Price Target to $25 From $35, Keeps Equal-Weight Rating
MT
11/08Third Quarter 2021 Financial Results Conference Call Earnings Presentation
PU
11/08Invitae Posts Wider Q3 Loss as Sales Rise, Lowers 2021 Revenue Guidance; Shares Slump 1..
MT
11/08INVITAE : Q3 Earnings Snapshot
AQ
11/08Invitae Reports $114.4 Million in Revenue Driven by 296,000 in Billable Volume in Third..
PU
11/08Earnings Flash (NVTA) INVITAE CORPORATION Posts Q3 Loss $-0.81, vs. Street Est of $-0.7..
MT
More news
Analyst Recommendations on INVITAE CORPORATION
More recommendations
Financials (USD)
Sales 2021 464 M - -
Net income 2021 -471 M - -
Net Debt 2021 694 M - -
P/E ratio 2021 -7,06x
Yield 2021 -
Capitalization 3 484 M 3 484 M -
EV / Sales 2021 9,01x
EV / Sales 2022 6,72x
Nbr of Employees 2 900
Free-Float 97,4%
Chart INVITAE CORPORATION
Duration : Period :
Invitae Corporation Technical Analysis Chart | NVTA | US46185L1035 | MarketScreener
Technical analysis trends INVITAE CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 15,39 $
Average target price 35,67 $
Spread / Average Target 132%
EPS Revisions
Managers and Directors
Sean Emerson George Chairman, President & Chief Executive Officer
Roxi Wen Chief Financial Officer
Robert Nussbaum Chief Medical Officer
Eric Olivares Chief Science Officer
Layton Wedgeworth Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
INVITAE CORPORATION-63.19%3 484
EXACT SCIENCES CORPORATION-39.19%13 930
GUARDANT HEALTH, INC.-24.22%9 018
BGI GENOMICS CO., LTD.-29.92%5 792
ADAPTIVE BIOTECHNOLOGIES CORPORATION-57.11%3 552
SEEGENE, INC.-33.16%2 829